184. Murakami M, Masuda S, Ichiro KUDO (2003) Arachidonate release and prostaglandin
production by group IVC phospholipase A2 (cytosolic phospholipase A2gamma).
Biochem J 372(3):695–702
185. Singh N, Jabeen T, Sharma S, Somvanshi RK, Dey S, Srinivasan A, Singh TP (2006)
Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2:
structure of the complex formed between phospholipase A2 and diclofenac at 2.7 Å
resolution. Acta Crystallogr D Biol Crystallogr 62(4):410–416
186. Singh N, Kumar RP, Kumar S, Sharma S, Mir R, Kaur P, Srinivasan A, Singh TP (2009)
Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of
phospholipase A2 complexed with indomethacin at 1.4 Å resolution reveals the presence
of the new common ligand-binding site. J Mol Recognit 22(6):437–445
187. Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE,
Hartley LW, Jones ND, Mihelich ED, Olkowski JL (1995) Structure-based design of the first
potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat
Struct Mol Biol 2(6):458–465
188. Cha SS, Lee D, Adams J, Kurdyla JT, Jones CS, Marshall LA, Bolognese B, Abdel-Meguid
SS, Oh BH (1996) High-resolution X-ray crystallography reveals precise binding
interactions between human nonpancreatic secreted phospholipase A2 and a highly potent
inhibitor (FPL67047XX). J Med Chem 39(20):3878–3881
189. Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor
bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS ONE
7(4):e29828
190. Gill AL, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, Walker MT,
Congreve MS, Devine LA, Tisi D, O’Reilly M, Seavers LC, Davis DJ, Curry J, Anthony R,
Padova A, Murray CW, Carr RA, Jhoti H (2005) Identification of novel p38a MAP kinase
inhibitors using fragment-based lead generation. J Med Chem 48(2):414–426
191. Xu ZB, Chaudhary D, Olland S, Wolfrom S, Czerwinski R, Malakian K, Lin L, Stahl ML,
Joseph-McCarthy D, Benander C, Fitz L, Greco R, Somers WS, Mosyak L (2004) Catalytic
domain crystal structure of protein kinase C-? (PKC?). J Biol Chem 279(48):50401–50409
192. Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F,
Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C,
Sun Y, Thomsen NM, Wang C, Wang J, Peukert S (2017) Discovery of an acrylic acid based
tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for
ERa + breast cancer. J Med Chem 60(7):2790–2818
193. Kinoshita JH, Nishimura C (1988) The involvement of aldose reductase in diabetic
complications. Diabetes/Metabolism Res Rev 4(4):323–337
194. Pugliese G, Tilton RG, Williamson JR (1991) Glucose-induced metabolic imbalances in the
pathogenesis of diabetic vascular disease. Diabetes/Metabolism Res Rev 7(1):35–59
195. Wilson DK, Bohren KM, Gabbay KH, Quiocho FA (1992) An unlikely sugar substrate site
in the 1.65 A. Science 257:81
196. Bohren KM, Grimshaw CE, Lai CJ, Harrison DH, Ringe D, Petsko GA, Gabbay KH (1994)
Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity
in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of
the Y48H mutant enzyme. Biochemistry 33(8):2021–2032
197. Velmurugan D, Malar Selvi U, Mythily U, Rao K, Rajarajeshwari R (2012) Structure-based
discovery of anti-viral compounds for hepatitis B & C, human immunodeficiency, and
dengue viruses. Curr Bioinform 7(2):187–211
198. Velmurugan D, Mythily U, Rao K (2014) Design and docking studies of peptide inhibitors
as potential antiviral drugs for dengue virus ns2b/ns3 protease. Protein Pept Lett 21(8):815–
827
199. Kutumbarao NHV, Velmurugan D (2016) Structural analysis and molecular modeling
studies of fatty acids and peptides binding with NS2B/NS3 dengue protease. J Emerg Dis
Virol 2(4); 2473-1846
304
D. Velmurugan et al.
production by group IVC phospholipase A2 (cytosolic phospholipase A2gamma).
Biochem J 372(3):695–702
185. Singh N, Jabeen T, Sharma S, Somvanshi RK, Dey S, Srinivasan A, Singh TP (2006)
Specific binding of non-steroidal anti-inflammatory drugs (NSAIDs) to phospholipase A2:
structure of the complex formed between phospholipase A2 and diclofenac at 2.7 Å
resolution. Acta Crystallogr D Biol Crystallogr 62(4):410–416
186. Singh N, Kumar RP, Kumar S, Sharma S, Mir R, Kaur P, Srinivasan A, Singh TP (2009)
Simultaneous inhibition of anti-coagulation and inflammation: crystal structure of
phospholipase A2 complexed with indomethacin at 1.4 Å resolution reveals the presence
of the new common ligand-binding site. J Mol Recognit 22(6):437–445
187. Schevitz RW, Bach NJ, Carlson DG, Chirgadze NY, Clawson DK, Dillard RD, Draheim SE,
Hartley LW, Jones ND, Mihelich ED, Olkowski JL (1995) Structure-based design of the first
potent and selective inhibitor of human non-pancreatic secretory phospholipase A2. Nat
Struct Mol Biol 2(6):458–465
188. Cha SS, Lee D, Adams J, Kurdyla JT, Jones CS, Marshall LA, Bolognese B, Abdel-Meguid
SS, Oh BH (1996) High-resolution X-ray crystallography reveals precise binding
interactions between human nonpancreatic secreted phospholipase A2 and a highly potent
inhibitor (FPL67047XX). J Med Chem 39(20):3878–3881
189. Levinson NM, Boxer SG (2012) Structural and spectroscopic analysis of the kinase inhibitor
bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS ONE
7(4):e29828
190. Gill AL, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, Walker MT,
Congreve MS, Devine LA, Tisi D, O’Reilly M, Seavers LC, Davis DJ, Curry J, Anthony R,
Padova A, Murray CW, Carr RA, Jhoti H (2005) Identification of novel p38a MAP kinase
inhibitors using fragment-based lead generation. J Med Chem 48(2):414–426
191. Xu ZB, Chaudhary D, Olland S, Wolfrom S, Czerwinski R, Malakian K, Lin L, Stahl ML,
Joseph-McCarthy D, Benander C, Fitz L, Greco R, Somers WS, Mosyak L (2004) Catalytic
domain crystal structure of protein kinase C-? (PKC?). J Biol Chem 279(48):50401–50409
192. Burks HE, Abrams T, Kirby CA, Baird J, Fekete A, Hamann LG, Kim S, Lombardo F,
Loo A, Lubicka D, Macchi K, McDonnell DP, Mishina Y, Norris JD, Nunez J, Saran C,
Sun Y, Thomsen NM, Wang C, Wang J, Peukert S (2017) Discovery of an acrylic acid based
tetrahydroisoquinoline as an orally bioavailable selective estrogen receptor degrader for
ERa + breast cancer. J Med Chem 60(7):2790–2818
193. Kinoshita JH, Nishimura C (1988) The involvement of aldose reductase in diabetic
complications. Diabetes/Metabolism Res Rev 4(4):323–337
194. Pugliese G, Tilton RG, Williamson JR (1991) Glucose-induced metabolic imbalances in the
pathogenesis of diabetic vascular disease. Diabetes/Metabolism Res Rev 7(1):35–59
195. Wilson DK, Bohren KM, Gabbay KH, Quiocho FA (1992) An unlikely sugar substrate site
in the 1.65 A. Science 257:81
196. Bohren KM, Grimshaw CE, Lai CJ, Harrison DH, Ringe D, Petsko GA, Gabbay KH (1994)
Tyrosine-48 is the proton donor and histidine-110 directs substrate stereochemical selectivity
in the reduction reaction of human aldose reductase: enzyme kinetics and crystal structure of
the Y48H mutant enzyme. Biochemistry 33(8):2021–2032
197. Velmurugan D, Malar Selvi U, Mythily U, Rao K, Rajarajeshwari R (2012) Structure-based
discovery of anti-viral compounds for hepatitis B & C, human immunodeficiency, and
dengue viruses. Curr Bioinform 7(2):187–211
198. Velmurugan D, Mythily U, Rao K (2014) Design and docking studies of peptide inhibitors
as potential antiviral drugs for dengue virus ns2b/ns3 protease. Protein Pept Lett 21(8):815–
827
199. Kutumbarao NHV, Velmurugan D (2016) Structural analysis and molecular modeling
studies of fatty acids and peptides binding with NS2B/NS3 dengue protease. J Emerg Dis
Virol 2(4); 2473-1846
304
D. Velmurugan et al.